|
Patent landscape, scope, and claims: |
Scope of U.S. Patent 11,439,629: CYP2D6-genotype–guided dosing of a VMAT2 inhibitor for chorea using ~40 mg/day (then optional up-titration to ~80 mg/day)
United States Patent 11,439,629 is a US method-of-treatment patent that claims a CYP2D6 poor-metabolizer–specific dosing regimen for a specific VMAT2 inhibitor salt (including a ditosylate salt and polymorphic Form I), where the indication is hyperkinetic movement disorder, specifically chorea (including Huntington’s disease chorea). The claims are tightly anchored to: (i) the CYP2D6 poor metabolizer status, (ii) defined CYP2D6 variants (G1846A and C100T, including AA and TT/CT genotypes), (iii) oral once-daily administration, and (iv) a dosage defined as “an amount equivalent to about 40 mg” measured by the free base identity “(S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-…-yl ester,” with optional titration to “about 80 mg” after one week.
Because you provided only the claims text and not the patent document itself, the analysis below is restricted to claim scope, likely enforceable coverage boundaries, and a patent-landscape framework derived from the claim elements you supplied (CYP2D6 pharmacogenomics, VMAT2 inhibitor, salt and polymorph, genotype-specific dosing, monitoring/QT prolongation). No Orange Book, prosecution history, or inventor/assignee-based landscape can be completed from the information provided.
What is the claim scope of US Patent 11,439,629 for CYP2D6 poor metabolizers with chorea?
What does the patent claim at a high level?
The core claim set is directed to method(s) that combine:
- Patient phenotype: CYP2D6 poor metabolizer (with genotype embodiments)
- Drug class: VMAT2 inhibitor
- Specific active: (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester and pharmaceutically acceptable salts
- Dose and measurement basis: oral, once daily, and dose expressed as “equivalent to about 40 mg” (and in some claims, a subsequent increase to “equivalent to about 80 mg” after one week)
- Indication: hyperkinetic movement disorder = chorea (including chorea associated with Huntington’s disease)
How narrow is the “about 40 mg once daily” dosing requirement?
The claims explicitly require that the administered amount is equivalent to about 40 mg once daily, measured by the stated chemical identity. That anchors infringement risk to:
- dose level around 40 mg/day, and
- whether the dosing is implemented as once daily oral administration, and
- whether the “equivalence” is calculated to the same chemical basis (the claim repeats the same “measured by” phrase).
Claims that recite later up-titration to ~80 mg/day require timing and schedule (after one week) in those specific dependent claims (e.g., claim 17, claim 29, and claim 28/27 frameworks).
Which patient groups are in scope (phenotype and genotype)?
- Claim 1: method for a patient who is a CYP2D6 poor metabolizer.
- Claim 2–5: embodiments specifying poor metabolizer genotypes:
- CYP2D6G1846A (claim 3), including AA (claim 4)
- CYP2D6C100T including TT or CT (claims 5)
- Claims 18–27 and 31: method frameworks that require determining whether the patient is a poor metabolizer and then selecting between a “first” vs “second” dosing approach (claims 18 and 27), or specifically treating after determining the poor metabolizer (claim 31).
Practical enforceability boundary: any commercial regimen that does not target the same CYP2D6 poor-metabolizer status (or does not follow genotype-defined logic where claimed) reduces claim matching likelihood.
What indication wording does the patent cover?
- Claim 1 et seq. recite “hyperkinetic movement disorder” and specify “wherein the hyperkinetic movement disorder is chorea.”
- Dependent claims specify “chorea associated with Huntington’s disease” (claims 16, 26, 30, 32).
So the patent covers chorea broadly in its independent claim context, with Huntington’s disease chorea in dependent claims.
Which claims most directly protect the commercially relevant dosing algorithm and how do they differ?
Independent-method architecture
You provided four independent-like claim clusters (as written):
- Claim 1: direct treatment of a CYP2D6 poor metabolizer with ~40 mg/day once daily.
- Claim 18: test-then-treat method:
- administer VMAT2 inhibitor,
- subsequently determine poor metabolizer,
- reduce dosage to ~40 mg/day.
- Claim 27: conditional regimen:
- determine poor metabolizer status,
- if poor: administer first amount ~40 mg/day,
- if not poor: administer second amount ~40 mg/day for one week, then increase after one week (to up-titration logic; claim 29 specifies ~80 mg/day).
- Claim 31: administer a ~40 mg/day ditosylate regimen first, then determine poor metabolizer and continue the same amount.
Key differences in claim “trigger” and “timing”
- Claim 1: no upfront testing required; phenotype assumed/known.
- Claim 18: requires the sequence of (a) administer, (b) determine, (c) reduce.
- Claim 27: requires determining and branching dosing logic based on poor vs non-poor; includes continued ~40 mg/day for non-poor for one week then up-titration.
- Claim 31: requires starting with ditosylate and then determining poor metabolizer while maintaining the same ~40 mg/day.
Implication: real-world practices that start all patients at a uniform dose and then titrate based on genotype may map more directly to the “determining” and “reducing/increasing” elements in claims 18 and 27, rather than claim 1 alone.
What drug substance, salt forms, and polymorphs are claimed in US 11,439,629?
Specific VMAT2 inhibitor entity
Every claim that recites the active specifies:
- the (S)-enantiomer and the described stereochemical configuration
- “and pharmaceutically acceptable salts thereof”
That is not “any VMAT2 inhibitor.” It is directed to a specific chemical identity.
Salt specificity escalation
- Claim 11: pharmaceutically acceptable salt (generic “salt”).
- Claim 12: ditosylate salt of the named active.
- Claim 13:ditosylate in polymorphic Form I.
These create layered protection:
- Broadest: method with “pharmaceutically acceptable salts”
- Narrower: method specifying the ditosylate
- Narrowest: method specifying ditosylate + polymorphic Form I
Infringement design-around risk: switching to a different salt form (not ditosylate) or a different polymorph could avoid the dependent claim layers, while independent claim coverage may still remain if the independent claims are not limited to ditosylate/Form I (claim 1 is broader on salts: it recites the active “chosen from … and pharmaceutically acceptable salts thereof,” but also recites the active identity as a named choice; the provided text does not show an explicit exclusion of non-ditosylate salts from the independent claim itself).
Formulation/dosage form
- Claim 10: administered in the form of a capsule.
So manufacturing choices (capsule vs tablet) may matter for claim 10, but not necessarily for independent methods unless the independent claims include the capsule limitation (from the provided text, only claim 10 does).
What genetic testing embodiments and CYP2D6 variants are covered?
The claim text explicitly includes:
Scope take: a regimen applied to “CYP2D6 poor metabolizers” in a clinically defined sense may still meet claim 1 (phenotype), but claims that specify the exact variants/genotypes add another matching dimension.
Does US 11,439,629 claim monitoring for adverse reactions and QT prolongation?
Monitoring is a specific method step in dependent claims
- Claim 6: “monitoring the patient for one or more exposure-related adverse reactions”
- Claim 7: lists multiple adverse reactions, including:
- somnolence, anticholinergic effects, balance disorders or falls, headache, akathisia, vomiting, nausea, arthralgia, QT prolongation, glucose/weight changes, respiratory infections, drooling, dyskinesia, extrapyramidal symptoms (non-akathisia), anxiety, insomnia, prolactin/ALP/bilirubin increases
- Claim 8: restricts list to somnolence and QT prolongation
- Claim 9: specifies QT prolongation as the adverse reaction
Practical enforceability
The monitoring language is a “method step.” A clinical protocol that does not include a monitoring step for the claimed exposure-related adverse reactions may avoid these dependent claim layers even if the core dosing is used.
What mechanistic exposure element is claimed (increased active metabolite exposure)?
Claim 14 adds a pharmacokinetic exposure comparison:
- increased exposure to the active metabolite of the VMAT2 inhibitor in CYP2D6 poor metabolizers versus non-poor when both receive the same amount
- Claim 15: exposure measured by Cmax or AUC0-∞
This matters for infringement theories based on:
- clinical trial design replication,
- label-based pharmacokinetic testing,
- and regimen development data.
What dosing titration pathways are claimed (including 1-week schedule)?
Up-titration after one week
- Claim 17: after one week, increase from ~40 mg/day to ~80 mg/day.
Conditional up-titration for non-poor metabolizers
- Claim 27: for non-poor metabolizers:
- administer ~40 mg/day for one week,
- subsequently administer increased amount after one week
- Claim 29 pins the “increased amount” to ~80 mg/day.
So the regimen has two dosing tracks:
- Poor metabolizers: ~40 mg/day (no up-titration step appears in the provided text for the poor metabolizer branch in claim 27; claim 27’s conditional language focuses on maintaining ~40 mg/day for poor metabolizers, with up-titration described for the non-poor branch)
- Non-poor metabolizers: ~40 mg/day for one week then up-titrate (to ~80 mg/day, per claim 29)
How could this patent map into a “Paragraph IV / generic entry” risk analysis for US?
From the claim text, infringement exposure for a generic or follow-on developer would most plausibly arise via:
- a labeled dosing regimen that matches the claimed method steps, including genotype-informed branching, or
- real-world prescribing that performs the same test-then-treat or conditional dosing and reduction/titration sequence.
Potential generic design-around levers
- Switch from the claimed active/salt (not covered for dependent salt/polymorph layers)
- Avoid genotype stratification in favor of an unclaimed approach (which could reduce matching to the “determining/branching” method claims, though claim 1 can be infringed by treating CYP2D6 poor metabolizers without explicit testing steps if phenotype is known)
- Change the dosing schedule so it is not “about 40 mg once daily” or not “increase after one week to about 80 mg”
- Avoid including monitoring for QT prolongation or the listed exposure-related adverse reactions in the regimen protocol (affects dependent monitoring claims)
What patent landscape questions remain open without the patent assignee and family details?
A full “landscape” normally requires:
- the patent’s title, assignee(s), inventor(s),
- the related family members (continuations/divisionals, PCT national phase),
- earlier priority dates and prosecution history,
- and Orange Book mappings to the approved drug product(s).
Those cannot be derived from the claims text you provided alone. As a result, the analysis below stays at claim-scope and likely coverage boundaries rather than enumerating other specific US or international patents.
Key Takeaways
- US 11,439,629 is a method-of-use/patient stratification patent centered on treating chorea with a specific VMAT2 inhibitor, using CYP2D6 poor metabolizer status to set an oral once-daily dose equivalent to ~40 mg/day.
- The claims go beyond phenotype by embedding specific CYP2D6 variants: G1846A (AA) and C100T (TT/CT).
- Salt and solid-state layers include dependent claims for ditosylate and ditosylate polymorphic Form I.
- Regimen mechanics matter: separate claims cover test-then-reduce (claim 18), conditional branching with up-titration after one week (claims 27 and 29), and start-then-determine while maintaining dose (claim 31).
- Safety/PK steps appear in dependent claims via monitoring exposure-related adverse reactions (including QT prolongation) and via a Cmax/AUC0-∞ exposure comparison to the active metabolite.
FAQs
-
Does US 11,439,629 cover only Huntington’s disease chorea?
No. The claims require “chorea” generally; Huntington’s disease chorea is covered in dependent claims.
-
Is the patent limited to a single VMAT2 inhibitor molecule?
The claims as provided specify the named stereochemically defined VMAT2 inhibitor and its pharmaceutically acceptable salts, not the entire VMAT2 class generically.
-
If a clinician treats CYP2D6 poor metabolizers with ~40 mg/day without explicit genotype testing, is there still infringement risk?
Yes for claim 1-style coverage, because the claim requires the patient be a CYP2D6 poor metabolizer, not that the method includes performing the test.
-
Do QT monitoring steps need to be performed to infringe dependent claims?
For monitoring-dependent claims (claims 6–9, 23–24), yes, the monitoring step is part of the claimed method.
-
Can a change in salt form avoid all patent coverage?
It may avoid dependent claim layers that require the ditosylate or ditosylate polymorphic Form I, but independent claim coverage may still apply depending on how “pharmaceutically acceptable salts” and the named active choice are construed in the independent claim text.
References (APA)
- United States Patent No. 11,439,629. Claims text provided by user.
More… ↓
⤷ Start Trial
|
